| name | ppgl-alpha-blocker-add-on-indication |
| description | Determines when to add calcium antagonists or metyrosine to an alpha-blocker regimen for inadequate blood pressure control in pheochromocytoma and paraganglioma (PPGL). Indications include blood pressure uncontrolled on maximal alpha-blocker dose, significant side effects from alpha-blocker monotherapy, or development of vasospastic angina during preoperative management, with metyrosine initiated at 0.5 g/day and titrated to a maximum of 4 g/day. |
Indication for Adding Calcium Antagonists or Metyrosine to Alpha-Blocker Regimen in PPGL
STEP 1 — Gather Information
Document current alpha-blocker type and dose, recent blood pressure measurements, adverse effects, and symptoms suggestive of vasospastic angina. If blood pressure is uncontrolled on maximal tolerated dose, significant side effects are present, or vasospastic angina occurs, proceed to Step 2; otherwise, continue current alpha-blocker monotherapy and reassess in 1–2 weeks.
STEP 2 — Rule In / Rule Out
Assess whether systolic/diastolic blood pressure exceeds target (<130/80 mmHg) despite maximal tolerated alpha-blocker dose. If yes, rule in inadequate blood pressure control and proceed to Step 3; if no, rule out inadequate blood pressure control and proceed to evaluate side effects/vasospastic angina in Step 3.
STEP 3 — Classify or Stratify
Evaluate for significant alpha-blocker–related adverse effects (e.g., severe drowsiness, hypotension, gastrointestinal upset) or new-onset vasospastic angina. If either is present, rule in need for add-on therapy; if absent, rule out need for add-on and maintain current regimen.
STEP 4 — Decide
Initiate a calcium antagonist (e.g., amlodipine 5 mg daily) as first-line add-on; if calcium antagonists are contraindicated, not tolerated, or ineffective after titration, add metyrosine starting at 0.5 g/day divided BID, titrate by 0.5 g/day every 2–3 days to a maximum of 4 g/day, aiming for blood pressure <130/80 mmHg and ≥50% reduction in urinary fractionated metanephrines.
Clinical Guardrails / Mimics / Pitfalls
Do not add metyrosine without baseline liver function tests and monitoring for sedation or crystalluria; avoid calcium antagonists in patients with severe hypotension or decompensated heart failure; do not abruptly discontinue alpha-blocker when initiating add-on therapy; avoid nonselective alpha-blockers (phenoxybenzamine) as they are unavailable in Japan; do not use metyrosine in pregnancy or lactation due to insufficient safety data.
Concrete Clinical Example
A 50‑year‑old patient with PPGL on doxazosin 16 mg daily presents with blood pressure 152/98 mmHg and reports mild flushing but no angina. After confirming maximal tolerated dose, amlodipine 5 mg daily is added; blood pressure improves to 126/80 mmHg after one week.
Source: Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025, Japan Endocrine Society, 2025, DOI:10.1507/endocrj.EJ25-0165
